U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07245368) titled 'Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma' on Nov. 17.
Brief Summary: Phase 1 of this study will consist of 2 parts
* Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC).
* Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously.
Phase 2a of this study is a randomized, double-blind, placebo-control...